Drug intelligence / Profile preview

APL-1202 + APL-1501

Development stage: Phase 3
Lead developer: Asieris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

APL-1202 and APL-1501 are two separate investigational drugs developed by Asieris Pharmaceuticals. APL-1202 (also known as nitroxoline) is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities. It is primarily being developed for bladder cancer indications, including non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). APL-1501 is described as a second-generation compound of APL-1202, retaining the oral administration route but with improved druggability through prodrug design.

Other names: nitroxoline

Targets

METAP2 (Methionine aminopeptidase 2)

Beyond the preview

Go deeper on APL-1202 + APL-1501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL-1202 + APL-1501.

Explore the full profile